Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement

DESCRIPTION Update of the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis. METHODS The USPSTF evaluated evidence on the diagnostic accuracy of risk assessment instruments for osteoporosis and fractures, the performance of dual-energy x-ray absorptiometry and peripheral bone measurement tests in predicting fractures, the harms of screening for osteoporosis, and the benefits and harms of drug therapy for osteoporosis in women and men. RECOMMENDATIONS The USPSTF recommends screening for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors. (Grade B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men. (I statement).

[1]  S. Cummings,et al.  Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. , 2007, Archives of internal medicine.

[2]  H. Nelson,et al.  Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer , 2009, Annals of Internal Medicine.

[3]  S. Cummings,et al.  Use of alendronate and risk of incident atrial fibrillation in women , 2008 .

[4]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[5]  Christina Bougatsos,et al.  Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force , 2010, Annals of Internal Medicine.

[6]  A. Gafni,et al.  Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women , 2005, BMC musculoskeletal disorders.

[7]  T. Schacker,et al.  Annals of Internal Medicine , 1992 .

[8]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[9]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[10]  S. Cummings,et al.  Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study , 2008, BMJ : British Medical Journal.

[11]  Ingram Olkin,et al.  Meta-Analysis: Accuracy of Quantitative Ultrasound for Identifying Patients with Osteoporosis , 2006, Annals of Internal Medicine.

[12]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[13]  A. Díez-Pérez,et al.  The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  J. Peipert,et al.  Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale , 2002, Annals of Internal Medicine.

[15]  P. Shekelle,et al.  Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. , 2008, Annals of internal medicine.